PROCEPT BioRobotics 2026 Investor Day Summary Company Overview - **Company**: PROCEPT BioRobotics (NasdaqGM:PRCT) - **Industry**: Medical Technology, specifically focused on urology and BPH (Benign Prostatic Hyperplasia) treatment Key Points and Arguments Market Opportunity - Approximately **400,000 patients** undergo prostate procedures annually, with only **10% market penetration** by PROCEPT, indicating significant growth potential [2][3] - There are **8 million men** seeking therapy for BPH, many dissatisfied with current drug treatments [2] - Over **1 million men** discontinue medication annually due to ineffectiveness or side effects, presenting an additional opportunity [3] Technology and Clinical Evidence - PROCEPT has developed a **game-changing technology** for BPH treatment, with over **125,000 patients** treated and **900 instruments** installed globally [4][5] - The company emphasizes the importance of clinical evidence and aims to demonstrate effective execution in the field to drive market share [4] Reimbursement and Pricing Strategy - Transitioned to **Category I reimbursement** on January 1, 2026, which enhances the narrative around reimbursement and reduces previous uncertainties [5] - Handpiece pricing has seen a **$300 increase**, with expectations for **average selling price (ASP)** to reach **$3,500** in 2026 [11] Revenue Management - Eliminated end-of-quarter volume discounts to stabilize revenue and improve ASP, leading to more predictable ordering patterns [8][9] - Anticipates a **1-to-1 ratio** of handpiece sales to procedures, which is a conservative estimate given the addition of **200+ systems** in 2026 [13][14] Sales Organization Changes - Integrated clinical and sales support teams under a single regional leader to optimize resource allocation and improve performance [15][17] - Aimed to reduce the time from purchase order to first procedures by **50%** through better coordination [21] Strategic Focus Areas 1. **Accelerating Procedure Growth**: Targeting the **10% penetration** in the surgical market and increasing awareness of Aquablation therapy [54][56] 2. **Path to Profitability**: Emphasizing the need for a clear path to profitability and improved margins [4][10] 3. **Advancing Evidence and Innovation**: Continuing to invest in clinical evidence and exploring new indications, including prostate cancer treatment [45][46] Patient-Centric Approach - Highlighting the importance of preserving **urinary and sexual function** while providing effective symptom relief [34][42] - Addressing the misalignment between physician assumptions and patient desires regarding BPH treatment [63][64] - Developing targeted patient education initiatives to increase awareness and understanding of Aquablation therapy [68] Competitive Landscape - Positioning Aquablation as a superior alternative to traditional TURP procedures, which have been around for over **100 years** [31] - Emphasizing the unique benefits of Aquablation, including reduced complications and better long-term outcomes compared to other therapies [30][43] Future Growth Opportunities - Exploring leasing pilot programs to attract customers hesitant about capital expenditures [29] - Anticipating significant growth in the prostate cancer treatment market, leveraging existing technology and expertise [45][49] Additional Important Insights - The company is committed to educating both patients and clinicians about the benefits of Aquablation, aiming to shift perceptions and increase adoption [56][67] - The focus on **durability** and **long-term outcomes** is critical, as many contemporary BPH therapies struggle to maintain market momentum due to lack of sustained effectiveness [62] This summary encapsulates the key insights and strategic directions discussed during the PROCEPT BioRobotics 2026 Investor Day, highlighting the company's growth potential, innovative technology, and commitment to patient-centered care.

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $76.4 million, representing a 12% year-over-year growth [12] - U.S. revenue for the quarter was $66.6 million, reflecting a 10% growth compared to the prior year [12] - Gross margin for Q4 2025 was 60.6%, down from 64% in Q4 2024, primarily due to lower-than-expected U.S. consumable revenue and a one-time voluntary field action [15] - Net loss for Q4 2025 was $29.8 million, compared to a net loss of $18.9 million in Q4 2024 [16] - Adjusted EBITDA was a loss of $19 million in Q4 2025, compared to a loss of $10.3 million in the prior year [16] Business Line Data and Key Metrics Changes - Completed approximately 12,200 U.S. procedures in Q4 2025, representing approximately 69% year-over-year growth [12] - Handpieces sold totaled 9,400 units at an average selling price of approximately $3,340, reflecting a 5% price increase compared to Q3 2025 [12][10] - Total U.S. handpiece and other consumable revenue was $34 million in Q4 2025, representing 16% growth compared to Q4 2024 [12] - Sold 65 new HYDROS systems in Q4 2025, with an installed base of 718 systems, representing a 42% increase compared to year-end 2024 [14] Market Data and Key Metrics Changes - International revenue in Q4 2025 was $9.8 million, representing year-over-year growth of 25% [14] - The company expects 2026 total U.S. procedures to be in the range of 60,000-64,000, representing growth of approximately 39%-48% [17] Company Strategy and Development Direction - The company is shifting operational focus towards increasing procedure volume, expanding margins, and achieving profitability [6] - A new integrated regional structure for the commercial team has been established to ensure better coordination around customer success and procedure growth [7] - A dedicated launch team has been formed to drive consistent launches and improve downstream utilization [7] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q4 financial performance was lower than anticipated but emphasized that changes made are critical for sustainable high growth and a clear path to profitability [21] - The company is resetting 2026 guidance to $390 million-$410 million, representing annual growth of 27%-33% [10] - Management expressed confidence in the long-term growth and profitability trajectory despite short-term disruptions [18] Other Important Information - Cash, cash equivalents, and restricted cash totaled $285 million as of December 31, 2025, providing a strong balance sheet to support strategic priorities [16] - The company plans to provide a detailed multi-year look at financial guidance during the upcoming Investor Day [11] Q&A Session Summary Question: What unfolded in Q4 regarding handpiece sales? - Management indicated that the softness in handpiece sales was influenced by customer purchasing behavior and the elimination of bulk purchase discounts, leading to a more aligned sales model with procedure volumes [24][25] Question: Why is there confidence in the back half of 2026? - Management explained that as the sales force matures into the new alignment, they expect to see benefits in procedure growth, particularly in the second half of the year [29] Question: What is the confidence in achieving a 1-to-1 ratio of handpiece sales to procedures in 2026? - Management stated that historical data showed handpiece sales were typically higher than procedure volumes, but they are now modeling a 1-to-1 ratio based on recent changes in business practices [34][35] Question: What was the impact of the field action on gross margin? - Management clarified that the field action was a one-time, non-recurring event that had no patient safety issues and was contained to Q4, impacting gross margin by approximately 240 basis points [37][38] Question: Is there any customer dissatisfaction due to the end-of-quarter bulk purchase deals being discontinued? - Management reported no anticipated customer dissatisfaction and noted that ordering patterns have remained stable despite the changes [42] Question: What is the stability of the sales force after the commercial restructuring? - Management confirmed that the sales team has remained stable with no higher attrition, and the restructuring is expected to enhance customer relationships over time [44][48]

Core Insights - Stereotaxis (STXS) has launched its Synchrony system in Europe and submitted a 510(k) application to the U.S. FDA, aiming to modernize interventional cath labs with a unified digital interface [1][5] - The Synchrony system enhances workflow, visualization, and connectivity, positioning Stereotaxis to expand its market presence in both robotic and non-robotic cath labs [2][4] Product Features - Synchrony features a 55-inch ultra-high-definition 4K display that integrates multiple system feeds into a single interface, providing near-zero latency video streams and customizable layouts [3] - The system is paired with SynX, a secure cloud-based application that enables remote connectivity, collaboration, and real-time monitoring, compliant with HIPAA and GDPR standards [3][4] Strategic Vision - Synchrony and SynX are foundational platforms designed to support future advancements, including AI-driven automation and long-distance robotic procedures, aligning with Stereotaxis' long-term digital surgery vision [4] - The CE Mark approval allows for commercial rollout in EU markets, while the FDA submission paves the way for potential entry into the U.S. market, enhancing Stereotaxis' geographic reach [5] Competitive Landscape - Stereotaxis competes with key players like Intuitive Surgical (ISRG), which has advanced its da Vinci 5 platform with new software features and gained CE Mark approval for broader international rollout [6][7] - Microbot Medical (MBOT) has achieved FDA clearance for its LIBERTY Endovascular Robotic System, marking a significant milestone in the endovascular robotics market [8][10] - PROCEPT BioRobotics (PRCT) reported strong revenue growth and wider adoption of its Aquablation therapy, indicating a competitive environment in robotic-assisted surgical solutions [11][12]

Core Viewpoint - ProVerum has successfully completed a $80 million Series B funding round to advance its ProVee system, a novel treatment option for benign prostatic hyperplasia (BPH) patients, positioned between medication and surgery [2][3]. Company and Team - ProVerum was founded by two researchers from Trinity College Dublin, Conor Harkin and Ríona Ní Ghriallais, who identified a gap in treatment options for BPH patients [4][5]. - The company has a small team of approximately 30 people, focusing on integrating material engineering, urology, and industry transformation to expedite product development [5]. Product and Technology - ProVee is a "reversible" prostate stent designed to alleviate symptoms of BPH, which significantly impacts patients' quality of life [6][10]. - The stent addresses a significant treatment gap between medication and surgery, providing a less invasive option for patients [6][24]. - ProVee's design avoids common issues associated with traditional metal stents, such as encrustation and irritation, and is adaptable to various anatomical structures [15][19]. Clinical Trials and Market Significance - The ProVIDE study, a multi-center, randomized, double-blind trial, included 221 BPH patients and demonstrated significant improvements in symptoms and safety [19][21]. - Results showed that patients receiving ProVee experienced a notable reduction in International Prostate Symptom Score (IPSS) and improved urinary flow rates without serious adverse events [21][24]. - ProVee aims to fill the "middle layer" treatment space, reducing the burden on patients and healthcare systems by offering a simple outpatient procedure [23][24]. Industry Observation - The global BPH patient population exceeds 94 million, with many not receiving effective treatment, highlighting a substantial market opportunity for ProVee [24][25]. - ProVee's unique features, such as reversibility and outpatient applicability, position it favorably against existing treatments like UroLift and Rezūm [25][27]. Conclusion - ProVerum's ProVee stent represents a potential breakthrough in BPH treatment, aiming to redefine patient experiences and fill a critical gap in the market between medication and surgical options [25][27].